https://www.wehi.edu.au/news/world-first-experimental-cancer-treatment-paves-way-for-clinical-trial/ * Skip to: * Home * Content * Footer navigation WEHI * WEHI.TV * What's on + Art of Science + Events + Discovery tours * News * Research Our research Finding better ways of detecting and treating a wide range of diseases, and helping our community to live long and healthy lives. Overview Diseases Areas of research Technologies Researchers and labs Collaborative centres Research facilities Clinical trials Business development and ventures * About About WEHI Where the world's brightest minds collaborate and innovate to make discoveries that will help us to live healthier for longer. About WEHI Contact us Our values Diversity and inclusion Reconciliation Our people Alumni Organisational structure History Awards Annual reports Strategic plan * Careers and education Working and studying at WEHI WEHI promotes a scientific environment that emphasises innovation, collaboration and excellence. Careers Working at WEHI Scientific positions Professional positions Education Studying at WEHI PhD Honours Masters Undergraduate Clinician-scientist training Work experience Student research projects Student association Students in focus Learning Hub * Donate * Support us + WEHI * Research * About * Careers & Education * Support Us * WEHI.TV * News * What's on * Governance and policy * Information * Staff and students Additional Links * FAQs * Publications repository Connect with WEHI * Business development and ventures * Contact us * Illuminate Newsletter Stay up-to date Instagram YouTube Facebook Twitter LinkedIn Back Research overview Diseases Areas of research Technologies Researchers and labs Collaborative centres Research facilities Clinical trials Business development and ventures Back About Overview Our values Diversity and inclusion Reconciliation Our people Alumni Organisational structure History Awards Annual reports Strategic plan Contact us Back Working at WEHI Scientific positions Professional positions Studying at WEHI PhD Honours Masters Undergraduate Clinician-scientist training Work experience Student research projects Student association Students in focus Learning Hub Back * Art of Science * Events * Discovery tours Back * Funding * Policies * Statements * Ethics and integrity * Advocacy * Terms of use Back * FAQs * Supplying to WEHI * Feedback and complaints Back * Catalyst * Workday * Students in focus Back Close Help us live healthier and longer lives. Support overview Support overview You can help stop Parkinson's disease Before every cure comes a breakthrough, before every WEHI breakthrough comes you. Other ways you can support our research Include us in your Will Fundraise for us Gifts in memory Major gifts Donate now Our supporters Our supporters Supporter stories Supporter stories If you would like to give to a specific research program or support the work of a particular researcher, contact our fundraising team today. 03 9345 2403 ... fundraising@wehi.edu.au More contact information Donate now - * News World-first experimental cancer treatment paves way for clinical trial 28 February 2025 Related topics * Brain cancer * The Brain Cancer Centre * News and features Media Enquiries +61 475 751 811 communications@wehi.edu.au Share this article * Link copied * Share on Facebook * Share on LinkedIn * Share on Twitter Sections in this article Testing treatment hypothesis Skip to section Testing treatment hypothesis * News World-first experimental cancer treatment paves way for clinical trial 28 February 2025 Share this article * Link copied * Share on Facebook * Share on LinkedIn * Share on Twitter Sections in this article Testing treatment hypothesis [brain-canc] An experimental treatment for an aggressive and lethal brain cancer has today been published in Nature Medicine, paving the way for a clinical trial to be conducted by researchers at The Brain Cancer Centre. The peer-reviewed paper details experimental treatment for glioblastoma developed by Professor Georgina Long AO, University of Sydney medical oncologist and Medical Director of the Melanoma Institute Australia. At a glance Publication of experimental treatment for glioblastoma paves the way for a clinical trial to be conducted by researchers at The Brain Cancer Centre. The international clinical trial will scientifically investigate the efficacy of the experimental approach within a large cohort of eligible glioblastoma patients. The Brain Cancer Centre was founded by Carrie's Beanies 4 Brain Cancer and established in partnership with WEHI, with support from the Victorian Government. Glioblastoma is a highly aggressive and lethal brain cancer with an average survival time of 12 to 18 months. Only 25% of patients survive more than one year and less than 5% survive more than 3 years. The new publication shares the experimental treatment given to a patient diagnosed with glioblastoma. Prof Long used her expertise in immunotherapy and drew on melanoma science to devise, lead and administer the treatment. It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of three checkpoint inhibitor immunotherapies (drugs that activate the immune system, instructing T-cells to kill tumour cells) administered prior to surgery. The paper details that, when surgically removed, the tumour treated with immunotherapy showed increased diversity, abundance and activation of immune cells, compared to the tumour prior to receiving immunotherapy. These immune cells may recognise and attack cancer cells: their increased presence may suggest a strong immune response. At the time of final submission of the journal paper, the patient had no clear signs of cancer recurrence after more than 18 months. "My hypothesis was that we could administer combination immunotherapy as first line treatment before surgery to boost the immune system and activate T-cells to target the brain tumour - an approach I had previously developed successfully in both stage 3 melanoma and melanoma that had spread to the brain," said lead author, Prof Long. "This has never been done before and what this trial will do is establish whether this approach is feasible or effective for the treatment of glioblastoma." Testing treatment hypothesis An Australian-led international clinical trial will scientifically investigate the efficacy of the approach within a large cohort of eligible glioblastoma patients and could commence within a year. The study will trial the use of double immunotherapy. In some patients, double immunotherapy will be combined with chemotherapy. The trial will be led by The Brain Cancer Centre, which has world-leading expertise in glioblastoma. "I am delighted to be handing the baton to Dr Jim Whittle, a leading Australian neuro-oncologist at Peter MacCallum Cancer Centre, The Royal Melbourne Hospital and Co-Head of Research Strategy at The Brain Cancer Centre, to commence a broader scientific study to scientifically determine if - and how - this process might work in treating glioblastoma," said Prof Long, who also secured drug access for the clinical trial. "While we are buoyed by the results of this experimental treatment so far, a clinical trial in a large group of patients would need to happen before anyone could consider it a possible breakthrough." Dr Whittle, also a laboratory head at WEHI, said: "We are pleased to be able to build on this exciting work by diving into the process of designing a clinical trial, which takes time, care and accuracy. "When that process is complete, the result will be a world first clinical trial that enables us to thoroughly test the hypothesis against a representative sample of patients." The Brain Cancer Centre was founded by Carrie's Beanies 4 Brain Cancer and established in partnership with WEHI with support from the Victorian Government. The centre brings together a growing network of world-leading oncologists, immunologists, neurosurgeons, bioinformaticians and cancer biologists. Commencement of recruitment for the clinical trial will be announced by The Brain Cancer Centre at a later date and will be limited to eligible patients. Share this article * Link copied * Share on Facebook * Share on LinkedIn * Share on Twitter Related topics * Brain cancer * The Brain Cancer Centre * News and features Media Enquiries +61 475 751 811 communications@wehi.edu.au Share this article * Link copied * Share on Facebook * Share on LinkedIn * Share on Twitter Sections in this article Testing treatment hypothesis Related articles * News and features Prominent UK scientist joins Snow Centre for Immune Health team 27 February 2025 * News and features How advanced drug discovery tech is fast-tracking new treatments 05 February 2025 * News and features New scientific leadership team for WEHI 05 December 2024 * News and features Sir Gustav Nossal Professor of Immunology to honour giant of Australian science 03 December 2024 * Lung cancer * News and features Battling lung cancer supervillains 22 November 2024 * Anaemia * News and features Women in science champion anaemia breakthrough 20 November 2024 View all news Support us Together we can create a brighter future Your support will help WEHI's researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones. Ways to support us Donate online Sign up to our quarterly newsletter Illuminate Find out about recent discoveries, community supporters and more. First name(Required) [ ] Last name(Required) [ ] Email(Required) [ ] Submit [ ] [ ] [ ] [ ] [ ] [ ] [ ] D[ ] Illuminate Summer 2024 View the current issue - WEHI The Walter and Eliza Hall Institute of Medical Research 1G, Royal Parade, Parkville Victoria, 3052, Australia (03) 9345 2555 ABN 12 004 251 423 Connect with WEHI * Business development and ventures * Contact us * Illuminate Newsletter Governance & Policy * Funding * Policies * Statements * Ethics and integrity * Advocacy * Terms of use Information * Scientific divisions * FAQs * Publications repository * Supplying to WEHI * Feedback and complaints Staff and students * Catalyst * Workday * Students in focus Stay up-to-date Instagram YouTube Facebook Twitter LinkedIn Help create a brighter future Donate online Aboriginal and Torres Straight Islander Flags We acknowledge the Wurundjeri people of the Kulin Nation as the traditional owners of the land where our campuses are located, and recognise their continuing connection to Country and community. WEHI is committed to fostering an inclusive workplace where people with diverse identities can flourish in a safe and supportive environment. * Terms of use * Privacy Policy * Sitemap (c) WEHI 2025 Close By using this website, you agree to our use of cookies in accordance with our Privacy Policy and Terms of use. Close